Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care

Despite the fact that Non-Small Cell Lung Cancer (NSCLC) represents the leading cause of cancer-related death in the western, after two decades of intensive clinical research, there still remains a substantial lack of consensus regarding the appropriate chemotherapeutic management of patients with advanced stage disease.For patients with metastatic disease and good performance status, what is considered “standard” treatment is a platinum-based doublet. Several meta-analyses have been performed in order to answer several questionable issues in the treatment of these p